Дезоксизоталол

Description

Deoxysotalol is a related impurity and structural analogue of sotalol, a non-selective beta-blocker with additional class III antiarrhythmic properties (potassium channel blockade, prolongation of cardiac repolarization). In pharmaceutical nomenclature, the compound is known as impurity A according to the European Pharmacopoeia (Sotalol EP Impurity A) and related compound C according to USP (Sotalol USP Related Compound C) - it is used as a reference standard for quality control of the substance and finished dosage forms of sotalol.

Basic Attributes

• CAS No: 16974-42-8
• Chemical formula: C12H20N2O2S
• Molecular Weight: 256.3644
• Exact weight: 256.125
• UNII: 2O703211HL
• DSSTox ID: DTXSID70168742
• HS code: 2935909550
• PSA specifications: 66.6
• XLogP3: 1.5

Physico-chemical characteristics

• Density: 1.157±0.06 g/cm3 (predicted value)
• Boiling point: 381.9±44.0°C (predicted value)

Structural difference from sotalol

Deoxysotalol lacks a hydroxyl group, which is present in the sotalol molecule and is necessary for full binding to beta-adrenergic receptors. Because of this, the compound does not have the significant beta-blocking activity of its parent drug and is considered primarily as a marker of purity in sotalol production rather than as a therapeutic agent in its own right.

Scope of application

• reference standard for quality control of the substance and finished forms of sotalol according to pharmacopoeial methods (Ph. Eur., USP)
• identification and quantification of impurities by HPLC methods
• structure-activity studies of beta-blockers and class III antiarrhythmic drugs
• study of pharmacological effects on smooth muscle contractility - in particular, studies of the effect on prostaglandin-induced (PGF2α and 15-methyl-PGF2α) contractions of the isolated rat uterus and potentiation of the contractile effect of oxytocin

Parent drug

Sotalol is a non-selective beta-adrenergic receptor antagonist that combines classical beta-blocking activity with a class III antiarrhythmic effect due to blockade of potassium channels and prolongation of the action potential of cardiomyocytes. Used to treat ventricular and supraventricular arrhythmias. Monitoring the content of deoxysotalol in a substance is an obligatory part of assessing the purity of the active substance during registration and production of the drug.

Significance for pharmacopoeial analysis

Sotalol has been used clinically for decades, and precise control of the impurity profile is a mandatory requirement of regulatory authorities when registering generics and monitoring the stability of the finished dosage form. Deoxysotalol, as one of the main related impurities, is included in the pharmacopoeial monographs for sotalol and is used by manufacturers and control laboratories to validate analytical methods for the quantification of impurities by HPLC.

Storage and transportation conditions

Store in a dry place, protected from light, at room temperature, in an airtight container. No special transport restrictions have been established for the substance as an analytical standard.